Manoj Chelvanambi - Concepedia

Author

Manoj Chelvanambi

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

M Chelvanambi, M. Chelvanambi, Manoj Chelvanambi

126

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Melanoma Institute Australia University of Pittsburgh The University of Texas Health Science Center at Houston University of California, San Francisco

About

Manoj Chelvanambi is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	567
2	Immunology	3	3	281
3	Health Sciences	1	1	162
4	Cell Biology	1	1	162
5	Endocrinology	1	1	124

Manoj Chelvanambi

Publications

841

Citations

H-Index

Page 1

	Year	Citations
Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome Rebecca Simpson, Erin R. Shanahan, Marcel Batten, Nature Medicine DysbiosisHost-microbe InteractionsImmunologyGut MicrobiologyGut-organ Axis	2022	216
STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment Manoj Chelvanambi, Ronald J. Fecek, Jennifer L. Taylor, Journal for ImmunoTherapy of Cancer	2021	165
Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells Yogesh Goyal, Gianna T. Busch, Maalavika Pillai, Nature Diverse Clonal FatesOncologyTumor HeterogeneityMedicineHomogeneous Cancer Cells	2023	162
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy Christopher P. Vellano, Michael G. White, Miles C. Andrews, Nature Hormonal ReceptorBreast CancerPharmacotherapyEndocrinologyMedicine	2022	124
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma Walter J. Storkus, Deena M. Maurer, Yan Lin, Journal for ImmunoTherapy of Cancer	2021	51
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma Christina L. Roland, Elise F. Nassif, Emily Z. Keung, Nature Cancer Surgical OncologyMedicineImmunologyNon-comparative Phase 2Pathology	2024	46
Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma Russell G. Witt, Samuel Cass, Tiffaney Tran, JAMA Dermatology	2023	22
Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma Sonja Ludwig, Chang‐Sook Hong, Beatrice M. Razzo, Cancer Immunology Immunotherapy Cancer ImmunosurveillanceMedicineImmunologyPathologyCombination Immunochemotherapies	2019	19
Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome Nan Deng, Laura Reyes-Uribe, Johannes F. Fahrmann, Clinical Cancer Research	2023	19
PPP2R1A mutations portend improved survival after cancer immunotherapy Yibo Dai, Anne Knisely, Mitsutake Yano, Nature	2025	17

Page 1